mRNA技术产品最新临床研究进展

Recent progress in clinical research of mRNA technologies

2020年全球首款mRNA新型冠状病毒肺炎疫苗获得紧急使用授权,并在临床试验和真实世界中展现出了优异的安全性和保护效力。由于mRNA技术原理的优势,mRNA能够有效激起体液免疫和细胞免疫反应。目前,mRNA技术在传染病预防和肿瘤治疗是重点研究方向,其在蛋白补充和基因治疗等方面也崭露头角。基于mRNA的技术产品将迎来更大的发展空间,对生物医药行业产生颠覆性的影响。

As the first mRNA-based COVID-19 vaccine received Emergency Use Authorization(EUA)in 2020,its great safety profile and high protection efficacy has been well demonstrated.As a result of its unique advantage in the mechanism of action,mRNA can effectively trigger strong humoral and cellular immune response.Of note,many other prophylactic or therapeutic mRNA vaccines developed for preventing different infectious diseases or treatment of cancer are under clinical trial investigations.mRNA-based protein supplementation and gene therapy also begin to emerge.There will be bigger stage for the development of mRNA technology-based products,posing a revolutionary effect in the field of biopharmaceuticals.